BOULDER, Colo., Sept. 19, 2017 /PRNewswire/ -- Array BioPharma
Inc. (Nasdaq: ARRY) announced today the closing of its underwritten
public offering of 24,069,766 shares of its common stock, which
includes 3,139,534 shares of common stock issued upon the exercise
in full of the option to purchase additional shares granted to the
underwriters, at a public offering price of $10.75 per share.
The total gross proceeds from the offering are $258.75
million, before underwriting discounts and commissions and offering
expenses.
J.P. Morgan Securities LLC and Cowen and Company, LLC acted as
joint book-running managers for the offering. Piper
Jaffray & Co. also acted as a bookrunner for the offering.
Stifel and Wells Fargo Securities, LLC acted as lead managers and
SunTrust Robinson Humphrey, Inc. acted as co-manager.
The shares were sold pursuant to an effective shelf registration
statement filed with the Securities and Exchange
Commission (the "SEC") that became effective. This press
release does not constitute an offer to sell, or the solicitation
of an offer to buy, these securities, nor will there be any sale of
these securities in any state or other jurisdiction in which such
offer, solicitation or sale is not permitted.
A final prospectus supplement relating to the offering was filed
with the SEC and is available on the SEC's web site
at www.sec.gov. Copies of the final prospectus supplement and
accompanying prospectus may be obtained by contacting: J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, New York11717, Attn: Prospectus
Department, telephone: 866-803-9204; or Cowen and Company, LLC, c/o
Broadridge Financial Services, 1155 Long Island
Avenue, Edgewood, New York,
11717, Attn: Prospectus Department, telephone: 631-274-2806 ;
or Piper Jaffray & Co., 800 Nicollet Mall,
J12S03, Minneapolis, MN 55402, Attn: Prospectus
Department, telephone: 800-747-3924.
About Array BioPharma
Array BioPharma Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of targeted small molecule drugs to treat
patients afflicted with cancer. Eight registration studies
are currently advancing related to seven Array-owned or partnered
drugs: binimetinib (MEK162), encorafenib (LGX818), selumetinib
(partnered with AstraZeneca), danoprevir (partnered with Roche),
ipatasertib (partnered with Genentech), larotrectinib (partnered
with Loxo Oncology) and tucatinib (partnered with Cascadian
Therapeutics).
CONTACTS:
|
Tricia
Haugeto
|
|
(303)
386-1193
|
|
thaugeto@arraybiopharma.com
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-announces-closing-of-public-offering-and-full-exercise-of-option-to-purchase-additional-shares-300521997.html
SOURCE Array BioPharma Inc.